Impact of rhG-CSF on Clinical Efficacy and Immune Cell Subsets after Initial Induction Chemotherapy in AML.

MLA

Zhou, Mei, et al. “Impact of RhG-CSF on Clinical Efficacy and Immune Cell Subsets after Initial Induction Chemotherapy in AML.” Clinical Laboratory, vol. 69, no. 2, Feb. 2023. EBSCOhost, https://doi.org/10.7754/Clin.Lab.2022.220436.

APA

Zhou, M., Zhang, Q., Ren, X. Y., An, F. R., Wang, Z. T., Wang, H. P., Liu, L. L., Zhai, Z. M., Dong, Y., & Tao, Q. S. (2023). Impact of rhG-CSF on Clinical Efficacy and Immune Cell Subsets after Initial Induction Chemotherapy in AML. Clinical Laboratory, 69(2). https://doi.org/10.7754/Clin.Lab.2022.220436

Chicago

Zhou, Mei, Qing Zhang, Xi Y Ren, Fu R An, Zhi T Wang, Hui P Wang, Lin L Liu, Zhi M Zhai, Yi Dong, and Qian S Tao. 2023. “Impact of RhG-CSF on Clinical Efficacy and Immune Cell Subsets after Initial Induction Chemotherapy in AML.” Clinical Laboratory 69 (2). doi:10.7754/Clin.Lab.2022.220436.